No Data
What's Going On With Arcutis Biotherapeutics Stock Monday?
Arcutis Biotherapeutics Unit Gets Health Canada Approval for Atopic Dermatitis Treatment
The Health Canada Has Approved Arcutis' Approved Zoryve (Roflumilast Cream 0.15%), For The Treatment Of Mild To Moderate Atopic Dermatitis In Adults And Children Ages 6 Years And Older
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT)
Jefferies Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $19
Jefferies Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $19
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}